anti-thymocyte globulin
- Generic Name
- anti-thymocyte globulin
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Not Applicable
Terminated
- Conditions
- Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable ImmunodeficiencyGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeChronic Granulomatous Disease
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00006054
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Not Applicable
- Conditions
- Purpura, Schoenlein-HenochGraft Versus Host DiseaseAnemia, Hemolytic, AutoimmuneRheumatoid ArthritisChurg-Strauss SyndromeHypersensitivity VasculitisWegener's GranulomatosisSystemic Lupus ErythematosusGiant Cell ArteritisPure Red Cell Aplasia
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00006055
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Not Applicable
- Conditions
- Chediak-Higashi SyndromeGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisVirus-Associated Hemophagocytic Syndrome
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
Not Applicable
Completed
- Conditions
- NeutropeniaSickle Cell AnemiaRed-Cell Aplasia, PureThalassemia Major
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00005893
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
Phase 1
Completed
- Conditions
- Fanconi's Anemia
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00005898
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
Phase 3
Completed
- Conditions
- Aplastic Anemia
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 224
- Registration Number
- NCT00004474
- Locations
- 🇺🇸
Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
Phase 2
Completed
- Conditions
- Aplastic Anemia
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004323
- Locations
- 🇺🇸
Center for Health Sciences, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath